ASBP

Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company. It develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. It has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. It also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.

Wall Street analysts forecast ASBP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASBP is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Aspire Biopharma Holdings Inc revenue for the last quarter amounts to 1.94K USD, decreased % YoY.

Aspire Biopharma Holdings Inc. EPS for the last quarter amounts to -0.04 USD, decreased -42.86 % YoY.

Aspire Biopharma Holdings Inc (ASBP) has 0 emplpoyees as of December 17 2025.

Today ASBP has the market capitalization of 11.21M USD.